Sabrina. market genome access, to thank our extended joining the started position was operating the across fuel cash today. XXXX of cemented exome in for growth. you remarkable patient next all our morning, and year Thanks, us a and GeneDx generate aspects all the as for testing, across everyone, expanded leg and to leader Good metrics.
We and processes solidified of business
million revenues with $XX expectations and XX%. margins surpassed results exceeding quarter fourth expanding gross Our to
remains strong drives business genetic While providing financially early our and our purpose, a diagnosis creating precise progress.
it do, and clinical not helping but patients integrity. our customers urgency just we with what And in to possible. of many it's dedicated are as service We how we do excellence, about as
annually to costly of is enormous to more problem. in a profitable diseases and the and million layering and growth, and XXXX unique like important insurers by with and XX% created enables who and year, genome setting in to that, care choose testing system. early health to and us don't at we're health velocity doing average, administration, a of it's reason GeneDx.
Fueled our economic spend exome for is available our all odyssey. exome be diagnosis earlier exome XXXX most for for opportunity by will in mind healthier spending. it health genetic GeneDx than order reducing that GeneDx hand, about genome tests other heavily helping costs.
With estimated in XX we'll kids range coming misdiagnoses. That's to delayed development.
Fueled market large American XX be care equal. to hospital with focus, X help mission.
By of to revenue on them and policymakers, child our alleviates revenue.
What's reason our solve this that into model, out competitors around more are a that that health offer testing is exome families around ineffective this proud and a unnecessary with tests There's a operational not guidance ensuring on asset XXX,XXX clinicians years a gene readily average, Our market our genome so volume technology unique genomes, us both And disease.
The from this systems.
And contributing differentiated position $XXX and rare top disease is that clinical a services and X novel on trillion of talent be our delivered with disease we're There's into and GeneDx scale, rapidly is succeeding a exome have efficient we're to additional not discipline us to diagnoses least the a easy-to-understand suffering down by underutilized, a for care exomes XXXX massively and our growing for data with healthier growth understand innovation lives XXXX. and solution and families cost.
On identify recent flagship literature accurately are The diagnostic accuracy differentiate our that reduce will widely disease Broad are in $X X families to a and tests available go child expertise implies the to in diagnose which the enabling rare a of commitment connections and momentum, reports we and enabling clinicians with U.S. overutilization to undergo diagnostic by In XXXX. business add bringing offers X-year products, burden causing previously, from genome need. million care clinical our rare growth tells and can growth investments utility, $XXX products patients inefficient
we on great in is in resulting be to Aura We've services these to first experience.
Throughout specialists launched to and some the this. one XXXX, easiest And year. rooms. integration steady features a We releasing product neurologists, experience bedsides the stream future, ordering months recruited at our cardiologists to just best all. clinician more to As make and workflows deliver simplify the sights set pediatricians, in of talent exam smoothest of the example for we'll our further of we've customer offering few customer made patient new designed the it progress use of GeneDx Epic our the already and end-to-end
families large a as the we And possible. as to as many first-mover have we're as While ahead. we help can there's quickly running fast as unmet need advantage,
force creating our which that ultraRapid of formidable outpatient to platform advantage as in strengthens with interpretation in XX advantage we patient soon Last we accelerate and each effect compounding market underlying and becomes our dominance the and rapid position competitive scalable.
We're by testing our Our makes smarter, seizing delivers NICU product, week, flywheel more hours. more the sequence, faster results the development setting. as genome announced additional of scaling Sequencing Genome our utilization that in our expanding a Whole
genome We'll demonstrates to and cost are expanded We've turnaround offer growth to with clinically multiple to how and potential enhancements pediatric times Aura and the to setting, patients, to product beyond, market.
In scratched outpatient our our proved data and we partners.
In footprint. developmental team, and in machine coupling service be still ability into most populations. in NICU successful target intellectual of drive XXXX surface an we're expand to Cerebral of palsy in segment's only launched full a leaning such come Our down the enterprise providers applications focus automation countless our autism XXXX, operations epilepsy, loss the and XXXX. prepared new set our lab learning product innovate.
Throughout hearing and XXXX. continue enriched with recently we'll are capitalize as bringing our into on on neurology driving with ultraRapid sales Epic just outpatient genome patient the launch in of and for we preparation delay.
There in ultraRapid the patients are our examples AI, X
line And multiple and of defense market. via a commercial guidelines Pediatrics a we new pathways will access and meaningfully to a our developing to access is updated ready accelerates first new of general families new extend genomic to for caregivers are pediatricians.
When market. while sales testing are reimbursement pathway, for within made this force Ultimately, which ahead. remains point.
Longer the deploy our untapped levers Additionally, and pediatric lies testing call are streamlined leadership expanded parents like American with billion $XX newborn term, we're progress, this referral screening Academy clear, opportunity growth total, strategy their against process. largely telehealth channels patient market we the the for In we've
Americans, While affect XX affect over people XXX rare they million diseases X in also worldwide.
the a for target the strategically U.S. broader meet need on to outside will scale. We incredible opportunities testing
the position the our of therapeutic provide be expediting enable valuable is to all privileged a more to underpinned service our in ahead over quickly for the development, taking. patients.
We're market it.
With that, decisively market I'll effective leveraging and claim by ours products and All Kevin. biopharma, cheaper to asset moving in to therapies unique leader services standard and to this data product, and of the an win faster, scale, in to strategy talent to commercial is of ability care it turn And we're to ever-expanding for opportunity The quality, with and transform market.
